WCLC 2022 | Targeted treatments for EGFR exon 20 insertion mutations in NSCLC

Julia Rotow, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of targeted therapies for EGFR exon 20 mutations in non-small cell lung cancer (NSCLC). EGFR exon 20 insertions did not have targeted treatment available until only a year ago. Now, there are two FDA approved targeted treatments for EGFR exon 20 insertions, the tyrosine kinase inhibitor, mobocertinib and the EGFR/MET bispecific antibody, amivantamab. Thus, there are now actionable options for almost all EGFR mutations that can be detected via next generation sequencing (NGS). This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.